Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.32) by 65.63 percent. This is a 70.97 percent decrease over losses of $(0.31) per share from the same period last year.